DDRD (DNA Damage Response Deficiency)

Almac’s Predictive Assay for DNA Damaging Agents

Almac has developed a gene expression assay to detect DNA damage response deficient tumors associated with loss of the FA/BRCA pathway. These tumours have been shown to benefit from DNA damaging agents such as anthracycline based chemotherapy.

This assay can predict outcomes following treatment with:

  1. DNA damaging drugs such as Anthracycline and Cyclophosphamide
  2. Novel DNA-damaging therapeutics such as PARP inhibitors

The DDRD assay was originally developed for use in early stage breast cancer but is currently being validated in other disease areas such as ovarian, esophageal and colorectal cancers.

Almac’s DDRD assay has the potential to be used as a companion diagnostic for DNA damaging therapy across a range of disease areas.

Related resources